Camber Capital Management LP - Q2 2020 holdings

$1.75 Billion is the total value of Camber Capital Management LP's 30 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 0.0% .

 Value Shares↓ Weighting
GSK  GLAXOSMITHKLINE PLCsponsored adr$122,370,000
+7.7%
3,000,0000.0%7.00%
+3.1%
NKTR  NEKTAR THERAPEUTICS$69,480,000
+29.7%
3,000,0000.0%3.98%
+24.3%
COLL  COLLEGIUM PHARMACEUTICAL INC$35,000,000
+7.2%
2,000,0000.0%2.00%
+2.7%
AMAG  AMAG PHARMACEUTICALS INC$33,584,000
+23.8%
4,390,0000.0%1.92%
+18.6%
AVRO  AVROBIO INC$23,558,000
+12.1%
1,350,0000.0%1.35%
+7.5%
STRO  SUTRO BIOPHARMA INC$4,656,000
-23.9%
600,0000.0%0.27%
-27.1%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TEVA PHARMACEUTICALS INDS LTD34Q3 20239.7%
BROOKDALE SR LIVING INC32Q3 20235.0%
PERRIGO CO PLC29Q3 20237.1%
TENET HEALTHCARE CORP28Q3 20238.5%
NEKTAR THERAPEUTICS28Q1 20229.8%
UNIVERSAL HLTH SVCS INC25Q3 20239.9%
MYRIAD GENETICS INC24Q3 20235.0%
SAREPTA THERAPEUTICS INC23Q3 20236.0%
MYLAN NV21Q3 202010.1%
AMAG PHARMACEUTICALS INC21Q3 20204.0%

View Camber Capital Management LP's complete holdings history.

Latest significant ownerships (13-D/G)

View Camber Capital Management LP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
13F-HR2023-11-14
SC 13G2023-10-30
13F-HR2023-08-14

View Camber Capital Management LP's complete filings history.

Compare quarters

Export Camber Capital Management LP's holdings